Related Experiment Video
Updated: May 10, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Stress hyperglycemia in acute ST-segment elevation myocardial infarction is a marker of left ventricular remodeling
Danijela Djordjevic-Radojkovic1, Goran Koracevic, Dragana Stanojevic
1Clinic for cardiovascular diseases, Clinical Center, Nis, Serbia.
Insights
Stress hyperglycemia (SH) in ST-elevation myocardial infarction (STEMI) significantly increases in-hospital mortality risk. SH may also indicate left ventricular (LV) remodeling one year post-STEMI.
Area of Science:
- Cardiology
- Endocrinology
- Internal Medicine
Background:
- Stress hyperglycemia (SH) in ST-elevation myocardial infarction (STEMI) is linked to increased in-hospital mortality.
- The role of SH as a predictor of long-term post-hospital risk and left ventricular (LV) remodeling remains debated.
Purpose of the Study:
- To evaluate the in-hospital and one-year risks associated with SH in STEMI patients.
- To determine if SH serves as a marker for LV remodeling post-STEMI.
Main Methods:
- A cohort of 275 STEMI patients undergoing reperfusion therapy was analyzed.
- Patients were stratified into three groups: pre-existing diabetes mellitus (DM), SH without DM, and neither DM nor SH.
- SH was defined as admission blood glucose ≥ 8 mmol/l.
Main Results:
- In-hospital mortality was highest in the SH without DM group (9.3%) compared to DM (5%) and control (1.6%) groups (P < 0.05).
- For patients without known DM, SH was associated with a 6.378-fold increase in in-hospital mortality.
- End-diastolic volume (EDV) significantly increased in the SH without DM group over one year (126 ± 37 to 145 ± 30 ml, P < 0.05), suggesting LV remodeling.
Conclusions:
- SH in STEMI patients is a significant predictor of high in-hospital mortality.
- SH may serve as a marker for adverse LV remodeling, evidenced by increased EDV over one year.
Introduction:
Stress hyperglycemia (SH) in STEMI is associated with high risk of in-hospital mortality. It is still controversial if SH is marker of high post-hospital risk.
Objectives:
The aim was to analyze in-hospital and one-year risk associated with SH in STEMI and to study if SH is marker of LV remodeling.
Methods:
We enrolled 275 patients who were admitted with first STEMI and reperfused. Patients were divided according to admission glycemia in three groups: (1) with diabetes mellitus (DM); (2) with SH, without DM and; (3) without both DM and SH. SH was defined as admission blood glucose level ≥ 8 mmol/l.
Results:
In-hospital mortality was higher in patients with known DM (5%) and highest in patients with SH without previous DM (9.3%), and only 1.6% in the third group, P < 0.05. In patients without known DM, SH was associated with 6.378-fold higher in-hospital mortality. Total mortality was double in group with SH without DM compared to the third group (13.9% versus 6.3%). EDV changed in patients with SH without DM from 126 ± 37 to 145 ± 30 ml after one year, P < 0.05.
Conclusion:
SH is associated with high in-hospital mortality risk and it could be marker of LV remodeling (significant increase of EDV during one year).
More Related Videos
09:35A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
Published on: November 15, 2024
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Hyperglycemia
Acute Coronary Syndrome III: Diagnostic Studies
Myocarditis I: Introduction